Pipeline Insight, 2025" report provides a comprehensive analysis of the pipeline landscape with insights on over 3 companies and their emerging drugs in clinical and nonclinical stages for ATTR-CM.

Key Takeaways ATTR-CM is a rare, progressive condition that causes protein deposits in the heart, making it harder for the heart to pump effectively. It can lead to serious issues like heart ...

This condition, called wild-type ATTR (ATTRwt) amyloidosis, primarily affects the heart. There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000 and ...

The Phase 1, open-label, multicenter dose-escalation study (NCT03336580) enrolled 21 patients with hereditary ATTR Amyloidosis (hATTR) to receive PRX004 intravenously once every 28 days for up to ...